Haizhong Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haizhong Zhu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Adam E. Richardson
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications - Anthony Mastracchio
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications - Ashley Wilson
Department of Lymphoma and Myeloma University of Texas MD Anderson Cancer Center Houston Texas
31 shared publications - Chin Pan
Department of Lymphoma and Myeloma AbbVie Bay Area 1000 Gateway Blvd. 1 N. Waukegan Rd. South San Francisco North Chicago California Illinois
31 shared publications - Christine Will
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications - Colleen Dowell
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
In vitro and in vivo combination of ABBV-MALT1 and venetoclax
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
In vitro and in vivo combination of ABBV-MALT1 and venetoclax
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Pan-lineage PRISM analysis of ABBV-MALT1 sensitivity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Pan-lineage PRISM analysis of ABBV-MALT1 sensitivity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Excel Workbook ABBV-MALT1 Pharmacology
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Excel Workbook ABBV-MALT1 Pharmacology
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Antiapoptotic complex formation in ABC-DLBCL xenografts after ABBV-MALT1 monotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Antiapoptotic complex formation in ABC-DLBCL xenografts after ABBV-MALT1 monotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Materials and Methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Materials and Methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Efficacy of ABBV-MALT1 the OCI-LY10 CDX model
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Efficacy of ABBV-MALT1 the OCI-LY10 CDX model
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Efficacy of ABBV-MALT1 across non-GCB PDX models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Efficacy of ABBV-MALT1 across non-GCB PDX models